Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Nadezda Dolgikh"'
Autor:
Johanna Rausch, Margarita M. Dzama, Nadezda Dolgikh, Hanna L. Stiller, Stephan R. Bohl, Catharina Lahrmann, Kerstin Kunz, Linda Kessler, Hakim Echchannaoui, Chun-Wei Chen, Thomas Kindler, Konstanze Döhner, Francis Burrows, Matthias Theobald, Daniel Sasca, Michael W.M. Kühn
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Externí odkaz:
https://doaj.org/article/90cd884f6971424f8a76fbebefe0d819
Autor:
Ufuk Erdogdu, Nadezda Dolgikh, Stephanie Laszig, Vinzenz Särchen, Michael T. Meister, Marek Wanior, Stefan Knapp, Cathinka Boedicker
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 2, Pp 109-119 (2022)
BH3 mimetics are promising novel anticancer therapeutics. By selectively inhibiting BCL-2, BCL-xL, or MCL-1 (i.e. ABT-199, A-1331852, S63845) they shift the balance of pro- and anti-apoptotic proteins in favor of apoptosis. As Bromodomain and Extra T
Externí odkaz:
https://doaj.org/article/0403c2302550453288f621f27f8c9d7f
Autor:
Annkathrin Koch, Birte Jeiler, Jens Roedig, Sjoerd J.L. van Wijk, Nadezda Dolgikh, Simone Fulda
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 5, Pp 539-550 (2021)
Burkitt's lymphoma (BL) is a highly aggressive form of B-cell non-Hodgkin's lymphoma. The clinical outcome in children with BL has improved over the last years but the prognosis for adults is still poor, highlighting the need for novel treatment stra
Externí odkaz:
https://doaj.org/article/746d29e524ac4212a6dfac6ce63571a4
Publikováno v:
Translational Oncology, Vol 16, Iss , Pp 101313- (2022)
The RAS/MEK/ERK genetic axis is commonly altered in rhabdomyosarcoma (RMS), indicating high activity of downstream effector ERK1/2 kinase. Previously, we have demonstrated that inhibition of the RAS/MEK/ERK signaling pathway in RMS is insufficient to
Externí odkaz:
https://doaj.org/article/9a54df46b2714aad8c741ac05aa28351
Autor:
Roman Fadeev, Alexey Chekanov, Marina Solovieva, Olga Bezborodova, Elena Nemtsova, Nadezda Dolgikh, Irina Fadeeva, Anatoly Senotov, Margarita Kobyakova, Yana Evstratova, Raisa Yakubovskaya, Vladimir Akatov
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 3, p 525 (2019)
One of the main problems in oncology is the development of drugs that cause the death of cancer cells without damaging normal cells. Another key problem to be solved is to suppress the drug resistance of cancer cells. The third important issue is to
Externí odkaz:
https://doaj.org/article/379792bc029340838acc1f88afcfb92d
Sequencing studies have revealed recurrent mutations in the RAS pathway in rhabdomyosarcoma (RMS). However, RAS effector pathways in RMS are poorly defined. Here, we report that coinhibition of NRAS or MEK plus PI3Kα triggers widespread apoptosis in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d8cfa7be74780c7b64d6adacd2510b
https://doi.org/10.1158/0008-5472.c.6510044.v1
https://doi.org/10.1158/0008-5472.c.6510044.v1
Suppl. Figure 1. NRAS depletion reduces cell viability of NRAS mutated RMS cells. Suppl. Figure 2. MEK162 and BYL719 synergize to induce apoptosis in NRAS-mutated RMS cells. Suppl. Figure 3. MEK162 and BYL719 synergize to induce apoptosis in NRAS-mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54cbf292d3806d3e9358e7d1117ae235
https://doi.org/10.1158/0008-5472.22418132.v1
https://doi.org/10.1158/0008-5472.22418132.v1
Autor:
Johanna Rausch, Margarita M. Dzama, Nadezda Dolgikh, Hanna Stiller, Stephan Bohl, Catharina Lahrmann, Kerstin Kunz, Linda Kessler, Hakim Echchannaoui, Chun-Wei David Chen, Thomas Kindler, Francis Burrows, Matthias Theobald, Daniel Sasca, Scott A. Armstrong, Michael Kuehn
Publikováno v:
Blood. 140:6226-6227
Autor:
Stefan Knapp, Christina Grimm, Cathinka Boedicker, Michal R. Schweiger, Marek Wanior, Michael Meister, Michelle Hussong, Julius C. Enßle, Nadezda Dolgikh, Simone Fulda
Publikováno v:
Oncogene. 39:3837-3852
Remodeling transcription by targeting bromodomain and extraterminal (BET) proteins has emerged as promising anticancer strategy. Here, we identify a novel synergistic interaction of the BET inhibitor JQ1 with the PI3Kα-specific inhibitor BYL719 to t
Autor:
Sjoerd J L van Wijk, Simone Fulda, Birte Jeiler, Jens Roedig, Nadezda Dolgikh, Annkathrin Koch
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 5, Pp 539-550 (2021)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 5, Pp 539-550 (2021)
Burkitt's lymphoma (BL) is a highly aggressive form of B-cell non-Hodgkin's lymphoma. The clinical outcome in children with BL has improved over the last years but the prognosis for adults is still poor, highlighting the need for novel treatment stra